CFDE Data Portal | Search WASH9P

	Label	Description
	WASH9P Gene (Entity type)	ENSG00000310527 - WAS protein family homolog 9, pseudogene
	GSE151090 verteporfin 2 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 8 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE172409 dopamine neuron 1 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 9 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE133087 metformin 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 9 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172409 dopamine neuron 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS

WASH9P

ENSG00000310527 - WAS protein family homolog 9, pseudogene

GSE151090 verteporfin 2 v 4 human up

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 8 v 10 human dn

A Gene Set from LINCS

GSE172409 dopamine neuron 1 v 4 human up

A Gene Set from LINCS

GSE226249 pirfenidone HL 0 v 6 human up

A Gene Set from LINCS

GSE205976 GSE205978 CEP83 knockout TIME 1 v 0 human dn

A Gene Set from LINCS

GSE100148 EZH2 inhibition 9 v 5 human up

A Gene Set from LINCS

GSE133087 metformin 3 v 2 human up

A Gene Set from LINCS

GSE100148 EZH2 inhibition 9 v 7 human up

A Gene Set from LINCS

GSE172409 dopamine neuron 1 v 0 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.